NCT01791894

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing

Detailed description

PRIMARY OBJECTIVES: I. To determine whether administration of arsenic trioxide (ATO) to patients with basal cell carcinoma is associated with a reduction in Gli messenger ribonucleic acid (mRNA) and protein levels in tumor biopsy samples, when compared to baseline levels. SECONDARY OBJECTIVES: I. To determine whether there is evidence of tumor size reduction of ATO against basal cell carcinoma in humans. OUTLINE: Patients receive arsenic trioxide intravenously (IV) over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Conditions

• Basal Cell Carcinoma of the Skin
• Recurrent Skin Cancer

Interventions

Type	Name	Description
DRUG	arsenic trioxide	Given IV

Timeline

• Start date: 2013-04-01
• Primary completion: 2013-11-01
• Completion: 2015-11-01
• First posted: 2013-02-15
• Last updated: 2018-06-08
• Results posted: 2016-10-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study